Opinion|Videos|January 15, 2025
Sequencing Therapies in LR-MDS
Author(s)Guillermo Garcia-Manero, MD, David Swoboda, MD
Panelists discuss second-line (2L) treatment strategies for lower-risk myelodysplastic syndrome (LR-MDS), focusing on how to choose a 2L treatment for patients refractory to first-line options, and provide an overview of recent updates from the IMerge trial (Santini et al, EHA 2024; Zeidan et al, JCO 2024), while considering the role of imetelstat in treatment sequencing according to NCCN Guidelines MDS-5.
Advertisement
Episodes in this series
- Please give an overview of 2L treatment strategies.
- If patients are refractory to the available 1L options, how would you choose a 2L treatment?
- Please give a brief overview of recent updates from IMerge (Santini et al, EHA 2024; Zeidan et al, JCO 2024).
- In your opinion, and considering NCCN Guidelines MDS-5, where do you see imetelstat in the treatment sequencing for LR-MDS?
- What can we learn from these studies and are there any remaining knowledge gaps to note?
Advertisement
Related to this article
ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials.
Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.
Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
ESMO 2026 Presidential Symposium II Showcases OS-Improving LBAs in Lung and GI Cancers
3
Key Takeaways From DeLLphi-305 at ESMO 2026
4
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
5